Form 4: Neumora Director Buys $5M in Shares via 10b5-1 Plan

Kristina Burow, a Director and 10% owner of Neumora Therapeutics, acquired nearly 2 million shares of common stock through a pre-planned ARCH Venture Fund transaction.

Summary

• Kristina Burow, a Director and 10% owner of Neumora Therapeutics, Inc. (NMRA), reported an acquisition of common stock.
• The transaction involved the purchase of 1,915,700 shares of common stock at a price of $2.61 per share.
• The acquisition is scheduled for October 27, 2025, and was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.
• Following this transaction, Kristina Burow beneficially owns a total of 33,895,555 shares of common stock, both directly and indirectly.
• Indirect beneficial ownership includes shares held by ARCH Venture Fund XII, L.P. (6,046,907 shares), ARCH Venture Fund VII, L.P. (1,387,228 shares), ARCH Venture Fund VIII Overage, L.P. (2,321,566 shares), ARCH Venture Fund X, L.P. (12,205,379 shares), and ARCH Venture Fund X Overage, L.P. (11,886,758 shares).
• Kristina Burow directly owns 47,717 shares of common stock.
• As an investment committee member or managing director of various ARCH Venture Partners entities, Ms. Burow may be deemed to share the power to direct the disposition and vote of the indirectly held shares, disclaiming beneficial ownership except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of shares by a director and 10% owner, albeit through a pre-planned transaction, generally signals confidence in the company's future prospects.

Positives

• The acquisition of a significant number of shares (1,915,700) by a director and 10% owner signals continued confidence in Neumora Therapeutics' long-term prospects.
• The purchase price of $2.61 per share is relatively low, potentially indicating a belief in future appreciation.

Negatives

• The reported transaction date of October 27, 2025, is in the future, indicating a pre-planned acquisition under a Rule 10b5-1 plan rather than an immediate, opportunistic purchase based on recent developments.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing, which primarily reports an insider transaction.

Industry Context

This insider transaction reflects a significant investor's continued commitment to Neumora Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector, but does not provide broader industry trend analysis.

Related Party Transactions

• The acquisition was made by ARCH Venture Fund XII, L.P., and Kristina Burow is an investment committee member of the general partner of this fund, as well as other ARCH funds that indirectly own shares. This constitutes a related party transaction in terms of beneficial ownership.

Stakeholder Impact

• Shareholders may view this significant insider purchase as a positive signal of management and major investor confidence in the company's long-term value.

Key Dates

Recommendation

The substantial acquisition of shares by a director and 10% owner, Kristina Burow, is a positive indicator of long-term confidence in Neumora Therapeutics. However, the transaction is explicitly noted as being made pursuant to a Rule 10b5-1 plan, with a future transaction date of October 27, 2025. This means the purchase is part of a pre-arranged trading plan, rather than an immediate, discretionary investment decision based on new, undisclosed information. While it reinforces insider commitment, it does not signal an urgent 'buy' opportunity. Therefore, a 'hold' recommendation is appropriate, acknowledging the insider's long-term conviction without suggesting immediate market action.

Keywords

Neumora Therapeutics, NMRA, Kristina Burow, ARCH Venture, Insider Trading, Form 4, Stock Purchase, Director, 10% Owner, Equity Acquisition, 10b5-1 Plan